Navigation Links
Dismantling pancreas cancer's armor
Date:2/20/2014

ating factor (GM-CSF), which attracted the Gr-MDSCs.

Strikingly, the Gr-MDSCs actively worked against T cells, a class of immune cell central to many immunotherapy strategies. T cells are often harnessed to fight tumors because they can recognize very specific molecules and destroy any cells expressing those molecules. But Gr-MDSCs prevented T cells from dividing and even induced their death.

Stromnes found this effect could be reversed, however, and the T-cell response activated, by depleting Gr-MDSCs. When she did so, she saw evidence not only that the T cells could now enter the tumors, but also that the tumors showed evidence of the type of cellular damage the T cells are designed to mete out.

"The findings are important because they show that the tumor microenvironment itself, and in particular a specific subset of cells in the tumor, is preventing T cells from trafficking to the tumor and mounting a response," Stromnes said. Importantly, humans also possess cells very similar to Gr-MDSCs, which strengthens the case that similar strategies could impact human pancreas cancer. Additionally, the damage wreaked on Gr-MDSC-depleted tumors appeared to release some of the pressure inside the tumor, allowing crushed blood vessels to open again and providing a potential avenue for chemotherapy.

'We want to put as big a hurt on pancreas cancer as possible'

The results are a backbone on which the team can begin designing a multipronged approach to pancreas cancer therapies, Stromnes noted. The findings show that a T-cell-based therapy alone may not be enough. Researchers must also take into account pancreas cancer's immunosuppressive strategies. "We're trying to get the helpful immune cells into the tumors, and our results show that to do that, we need to get rid of these inhibitory cells the tumors have co-opted," she said.

The team is now working to develop a T-cell therapy to take advantage of their new findings.
'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. UCLA study finds link between high-fat, high-calorie diet and pancreas cancer
2. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
3. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
4. Mini-Organ Would Mimic Pancreas to Treat Type 1 Diabetes
5. Artificial Pancreas Worked Overnight on Kids With Type 1 Diabetes
6. Artificial pancreas: The way of the future for treating type 1 diabetes
7. Pancreas stem cell discovery may lead to new diabetes treatments
8. A leap forward in the quest to develop an artificial pancreas
9. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
10. Statins Wont Hurt, Might Even Help, Your Pancreas: Study
11. New marker for identifying precursors to insulin-producing cells in pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dismantling pancreas cancer's armor
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/27/2014)... discarding microscopic warning signs about your health. , But a ... "going to waste." , Brigham Young University chemist Adam Woolley ... of kidney disease and prostate cancer in a few minutes. ... a tiny tube and see how far it goes. , ... will latch onto disease markers and nothing else. Urine from ...
(Date:10/27/2014)... a new therapy by watching others use it, Surprisingly ... New technology is like an influential colleague -- opinionated ... every five to seven days , CHICAGO --- ... they are persuaded to do so by an influential colleague, ... innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... 27, 2014 Jiwa Law Corporation now ... are involved in motor vehicle accidents. The corporation now ... and rehabilitation expenses up to a maximum of $150,000. ... or chiropractor treatments, medications, home support services, and medical ... huge impact on the way you live your life,” ...
(Date:10/27/2014)... -- For children with broken bones, ibuprofen is ... researchers report. Although both medications are ... injuries, oral morphine carries more risk for negative ... that orally administered morphine and other [narcotic painkillers] ... evidence for the oral administration of morphine in ...
Breaking Medicine News(10 mins):Health News:New insights into the development of ciliopathies 2Health News:Prostate cancer, kidney disease detected in urine samples on the spot 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:Jiwa Law Corporation Now Assists Clients With ICBC Claims for Motor Vehicle Accidents 2Health News:For a Child's Fracture, Use Ibuprofen, Not Morphine: Study 2
... problem often leading to diabetes and cardiovascular disease. Being ... // resistant, but not all overweight or obese people ... insulin resistance, however, it is too difficult to administer ... have come up with a simple way to identify ...
... new study was conducted by the Johns Hopkins Bloomberg School ... 55 and older. Researchers used magnetic resonance imaging// to determine ... changes in the brain correlated with the risk of stroke ... moderate alcohol consumption and a decrease in brain size of ...
... surgery, according to a new study done by researchers ... //results are due to medical or psychosocial factors. ... surgery than men. Most have attributed this to the fact ... and have fewer social supports. In this study, investigators from ...
... drugs that lower cholesterol levels, research shows they remain ... a patient is in the hospital or at a ... Foundation looked at the relationship between when lipid-lowering therapy ... outpatient setting and its long-term use. ,For the ...
... major complication of diabetes, despite the fact most are ... performed among the diabetic population. ,Researchers studied ... of about 900 diabetic patients who had been diagnosed ... for 20 years to assess how these microvascular changes ...
... may improve strength and mobility in patients with osteoarthritis.// ... osteoarthritis who were older than age 50. Patients were divided ... week in a swimming pool, the second exercised in a ... the water and gym programs focused on resistance exercises. ...
Cached Medicine News:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
Medicine Products: